Entrectinib showed activity and appeared to be safe in pediatric patients with recurrent or refractory solid tumors harboring NTRK1/2/3, ROS1, or ALK aberrations.
Evidence is provided for an association between CMV reactivation and poor OS of patients with head and neck cancer in the setting of high systemic inflammation.
The researchers speculated that the delivery of alternating electric fields to GBM cells may facilitate the delivery of chemotherapy.
According to researchers, neovascularization is more common in glioblastoma, and extravasation is more common in primary CNS lymphoma.
HPV gene signature was associated with outcomes in patients with HPV-related oropharyngeal cancers and could become a prognostic biomarker.
A review article highlighted the racial disparities in head and neck cancer incidence and identified how this relates to HPV infection.
Patients who had hybrid minimally invasive esophagectomy had a lower rate of surgery-related complications than those who had transthoracic open esophagectomy.
Clinical application of cerebrospinal fluid ctDNA analysis remains unclear.
ASCO reviewed and critiqued the College of American Pathologists guideline for human papillomavirus testing in head and neck cancer.
Durvalumab with or without tremelimumab deemed safe and effective in patients with recurrent or metastatic head and neck squamous cell carcinoma.
Pembrolizumab monotherapy and pembrolizumab plus chemotherapy prolonged OS in recurrent/metastatic HNSCC.
Prolonged postoperative and radiation intervals were associated with worse survival outcomes in patients with head and neck cancer.
Age and pretreatment comorbidities were shown to impact survival outcomes in patients with locally advanced laryngeal cancer.
These factors influenced the likelihood of depression in patients not given prophylactic antidepressants.
In a small group of head and neck cancer patients, biweekly doses of cetuximab in the maintenance setting appeared to be more tolerable than weekly doses.
The biomarker may be a predictor of response to treatment and cancer progression in nasopharyngeal carcinoma.
Previous studies have demonstrated that patients with head and neck cancer experience high levels of stress, anxiety, and psychosocial distress throughout the course of the disease.
Only a few studies have investigated the effectiveness of pazopanib and cetuximab, an angiogenesis inhibitor and EGFR inhibitor, respectively, for head and neck squamous cell carcinoma.
The anti-programmed death 1 (PD-1) antibody pembrolizumab was determined to be an effective second-line option for patients with head and neck cancers.
Previous studies have demonstrated that motolimod can induce positive immune responses, but it did not improve outcomes in the first-line setting in squamous cell carcinoma of the head and neck in the featured study.